Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae
- 9 October 2007
- journal article
- review article
- Published by Springer Nature in Neuroradiology
- Vol. 49 (11) , 873-888
- https://doi.org/10.1007/s00234-007-0300-7
Abstract
Introduction During the past three decades, improvements in the treatment of childhood leukemia have resulted in high cure rates, particularly for acute lymphoblastic leukemia (ALL). Unfortunately, successful therapy has come with a price, as significant morbidity can result from neurological affects which harm the brain and spinal cord. The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades. Methods and results In this review we discuss the poignant, historical aspects of CNS leukemia therapy, outline current methods of systemic and CNS leukemia therapy, and present imaging findings we have encountered in childhood leukemia patients with a variety of acute neurological conditions. A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy. Specific features related to CNS leukemia and associated short-term toxicities, both disease- and therapy-related, are emphasized in this review with the specific neuroimaging findings. Specific CNS findings are similarly important when treating acute myelogenous leukemia (AML), and details of leukemic involvement and toxicities are also presented in this entity. Conclusion Despite contemporary treatment approaches which favor the use of chemotherapy (including intrathecal therapy) over radiotherapy in the treatment of CNS leukemia, children still occasionally experience morbid neurotoxicity. Standard neuroimaging is sufficient to identify a variety of neurotoxic sequelae in children, and often suggest specific etiologies. Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy. It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute, specific, recognizable, and often serious neurological consequences.Keywords
This publication has 42 references indexed in Scilit:
- New Primary Neoplasms of the Central Nervous System in Survivors of Childhood Cancer: a Report From the Childhood Cancer Survivor StudyJNCI Journal of the National Cancer Institute, 2006
- Posterior reversible encephalopathy syndrome in children with cancerPediatric Blood & Cancer, 2005
- Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosisPediatric Blood & Cancer, 2004
- Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93Leukemia, 2001
- A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer GroupBlood, 2001
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trialBritish Journal of Haematology, 1998
- Prediction of Relapse of Pediatric Acute Myeloid Leukemia by Use of Multidimensional Flow CytometryJNCI Journal of the National Cancer Institute, 1996
- Treatment of Childhood Acute Nonlymphoblastic Leukemia: A ReviewCancer Investigation, 1993
- Treatment of childhood acute lymphocytic leukemiaThe Journal of Pediatrics, 1970